Literature DB >> 35543898

Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?

Hiroyuki Takamatsu1.   

Abstract

Entities:  

Year:  2022        PMID： 35543898     DOI： 10.1007/s12185-022-03371-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

Review 1.  Novel immunotherapies in multiple myeloma.

Authors:  Ken Ohmine; Ryosuke Uchibori
Journal:  Int J Hematol       Date:  2022-05-18       Impact factor: 2.490

Review 2.  Bringing mass spectrometry into the care of patients with multiple myeloma.

Authors:  David L Murray
Journal:  Int J Hematol       Date:  2022-04-26       Impact factor: 2.490

Review 3.  Progress of modern imaging modalities in multiple myeloma.

Authors:  Toshiki Terao; Kosei Matsue
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.490

4.  Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Authors:  Luciano J Costa; Saurabh Chhabra; Eva Medvedova; Bhagirathbhai R Dholaria; Timothy M Schmidt; Kelly N Godby; Rebecca Silbermann; Binod Dhakal; Susan Bal; Smith Giri; Anita D'Souza; Aric Hall; Pamela Hardwick; James Omel; Robert F Cornell; Parameswaran Hari; Natalie S Callander
Journal:  J Clin Oncol       Date:  2021-12-13       Impact factor: 50.717

Review 5.  Multiple myeloma with high-risk cytogenetics and its treatment approach.

Authors:  Ichiro Hanamura
Journal:  Int J Hematol       Date:  2022-05-09       Impact factor: 2.319
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.